PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Pramipexole - Parkinson's disease
PAD Profile : Pramipexole - Parkinson's disease
Keywords :
dopamine agonists, non-ergot-derived dopamine receptor agonists, PD, nocturnal akinesia
Brand Names Include :
Mirapexin, Oprymea, Pipexus
Traffic Light Status
Status 1 of 2.
Status :
Blue
Formulations :
- Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
- Non-ergot derived Dopamine agonists (or levodopa or monoamine oxidase B inhibitors) are a first-line treatment option in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
- Non-ergot derived Dopamine agonists are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy
- Non-ergot derived Dopamine agonists may be considered in the treatment of nocturnal akinesia in Parkinson's disease.
Initiation may be carried out in Primary Care but only after recommendation by a specialist.
Modifications to therapy should only be carried out on specialist advice.
Prescribers are reminded to prescribe generically and not by brand.
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism